AIMS: Muscle ring finger (MuRF) proteins have been implicated in the transmission of mechanical forces to nuclear cell signaling pathways through their association with the sarcomere. We recently reported that MuRF1, but not MuRF2, regulates pathologic cardiac hypertrophy in vivo. This was surprising given that MuRF1 and MuRF2 interact with each other and many of the same sarcomeric proteins experimentally. METHODS AND RESULTS: Mice missing all four MuRF1 and MuRF2 alleles [MuRF1/MuRF2 double null (DN)] were born with a massive spontaneous hypertrophic cardiomyopathy and heart failure; mice that were null for one of the genes but heterozygous for the other (i.e. MuRF1(-/-) //MuRF2(+/-) or MuRF1(+/-) //MuRF2(-/-) ) were phenotypically identical to wild-type mice. Microarray analysis of genes differentially-expressed between MuRF1/MuRF2 DN, mice missing three of the four alleles and wild-type mice revealed a significant enrichment of genes regulated by the E2F transcription factor family. More than 85% of the differentially-expressed genes had E2F promoter regions (E2f:DP; P<0.001). Western analysis of E2F revealed no differences between MuRF1/MuRF2 DN hearts and wild-type hearts; however, chromatin immunoprecipitation studies revealed that MuRF1/MuRF2 DN hearts had significantly less binding of E2F1 in the promoter regions of genes previously defined to be regulated by E2F1 (p21, Brip1 and PDK4, P<0.01). CONCLUSIONS: These studies suggest that MuRF1 and MuRF2 play a redundant role in regulating developmental physiologic hypertrophy, by regulating E2F transcription factors essential for normal cardiac development by supporting E2F localization to the nucleus, but not through a process that degrades the transcription factor.
AIMS: Muscle ring finger (MuRF) proteins have been implicated in the transmission of mechanical forces to nuclear cell signaling pathways through their association with the sarcomere. We recently reported that MuRF1, but not MuRF2, regulates pathologic cardiac hypertrophy in vivo. This was surprising given that MuRF1 and MuRF2 interact with each other and many of the same sarcomeric proteins experimentally. METHODS AND RESULTS:Mice missing all four MuRF1 and MuRF2 alleles [MuRF1/MuRF2 double null (DN)] were born with a massive spontaneous hypertrophic cardiomyopathy and heart failure; mice that were null for one of the genes but heterozygous for the other (i.e. MuRF1(-/-) //MuRF2(+/-) or MuRF1(+/-) //MuRF2(-/-) ) were phenotypically identical to wild-type mice. Microarray analysis of genes differentially-expressed between MuRF1/MuRF2 DN, mice missing three of the four alleles and wild-type mice revealed a significant enrichment of genes regulated by the E2F transcription factor family. More than 85% of the differentially-expressed genes had E2F promoter regions (E2f:DP; P<0.001). Western analysis of E2F revealed no differences between MuRF1/MuRF2 DN hearts and wild-type hearts; however, chromatin immunoprecipitation studies revealed that MuRF1/MuRF2 DN hearts had significantly less binding of E2F1 in the promoter regions of genes previously defined to be regulated by E2F1 (p21, Brip1 and PDK4, P<0.01). CONCLUSIONS: These studies suggest that MuRF1 and MuRF2 play a redundant role in regulating developmental physiologic hypertrophy, by regulating E2F transcription factors essential for normal cardiac development by supporting E2F localization to the nucleus, but not through a process that degrades the transcription factor.
Authors: A Brazma; P Hingamp; J Quackenbush; G Sherlock; P Spellman; C Stoeckert; J Aach; W Ansorge; C A Ball; H C Causton; T Gaasterland; P Glenisson; F C Holstege; I F Kim; V Markowitz; J C Matese; H Parkinson; A Robinson; U Sarkans; S Schulze-Kremer; J Stewart; R Taylor; J Vilo; M Vingron Journal: Nat Genet Date: 2001-12 Impact factor: 38.330
Authors: Abigail S McElhinny; Cynthia N Perry; Christian C Witt; Siegfried Labeit; Carol C Gregorio Journal: J Cell Sci Date: 2004-06-15 Impact factor: 5.285
Authors: G Eelen; I Vanden Bempt; L Verlinden; M Drijkoningen; A Smeets; P Neven; M R Christiaens; K Marchal; R Bouillon; A Verstuyf Journal: Oncogene Date: 2008-03-17 Impact factor: 9.867
Authors: Ekaterini Angelis; Alejandro Garcia; Shing S Chan; Katja Schenke-Layland; Shuxen Ren; Sarah J Goodfellow; Maria C Jordan; Kenneth P Roos; Robert J White; W Robb MacLellan Journal: Circ Res Date: 2008-04-17 Impact factor: 17.367
Authors: Megan T Quintana; Traci L Parry; Jun He; Cecelia C Yates; Tatiana N Sidorova; Katherine T Murray; James R Bain; Christopher B Newgard; Michael J Muehlbauer; Samuel C Eaton; Akinori Hishiya; Shin Takayama; Monte S Willis Journal: Am J Pathol Date: 2016-06-17 Impact factor: 4.307
Authors: Kristine M Wadosky; Jessica M Berthiaume; Wei Tang; Makhosi Zungu; Michael A Portman; A Martin Gerdes; Monte S Willis Journal: J Mol Endocrinol Date: 2016-02-09 Impact factor: 5.098
Authors: Ranjan Banerjee; Jun He; Carolyn Spaniel; Megan T Quintana; Zhongjing Wang; James Bain; Christopher B Newgard; Michael J Muehlbauer; Monte S Willis Journal: Metabolomics Date: 2014-07-14 Impact factor: 4.290
Authors: Roberto Mota; Traci L Parry; Cecelia C Yates; Zhaoyan Qiang; Samuel C Eaton; Jean Marie Mwiza; Deepthi Tulasi; Jonathan C Schisler; Cam Patterson; Tania Zaglia; Marco Sandri; Monte S Willis Journal: Am J Pathol Date: 2018-05-23 Impact factor: 4.307
Authors: Kristine M Wadosky; Jessica E Rodríguez; Rebecca L Hite; Jin-na Min; Bethany L Walton; Monte S Willis Journal: Am J Physiol Endocrinol Metab Date: 2014-01-14 Impact factor: 4.310
Authors: David I Brown; Brian C Cooley; Megan T Quintana; Cynthia Lander; Monte S Willis Journal: Int J Pept Res Ther Date: 2016-01-09 Impact factor: 1.931
Authors: Taylor A Mattox; Martin E Young; Carrie E Rubel; Carolyn Spaniel; Jessica E Rodríguez; Trisha J Grevengoed; Mathias Gautel; Zhelong Xu; Ethan J Anderson; Monte S Willis Journal: J Bioenerg Biomembr Date: 2014-04-15 Impact factor: 2.945